查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1307828

藥物建模軟體的全球市場 - 產業趨勢和2030年為止的預測

Global Drug modeling software Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 468 Pages | 商品交期: 請詢問到貨日

價格

全球藥物建模軟體的市場規模在2022年估算為85億435萬美金。該市場在2023年～2033年的預測期間將以9.2％的年複合成長率擴大，到2030年達到之前達到168億881萬美元。

本報告提供全球藥物建模軟體市場相關調查，提供市場概要，以及各零件，不同操作系統，各部署模式，不同企業規模，各用途，購買模式，各終端用戶，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第5章 全球藥物建模軟體市場，各零件

  • 概要
    • 軟體
  • 服務
    • 專業服務
    • 管理服務

第6章 全球藥物建模軟體市場，不同操作系統

  • 概要
  • WINDOWS
  • LINUX
  • MAC OS
  • 其他

第7章 全球藥物建模軟體市場，各部署模式

  • 概要
  • 雲端基礎
  • 混合為基礎的
  • 內部部署

第8章 全球藥物建模軟體市場，不同企業規模

  • 概要
  • 大企業規模
  • 中小企業規模

第9章 全球藥物建模軟體市場，各用途

  • 概要
  • 圖形分子建模
  • 基因序列分析
  • 蛋白質建模
  • 晶體結構建模
  • 化學格式
  • 高通量虛擬篩選
  • 氣體和溶液相反應
  • 醫學成像
  • 其他

第10章 全球藥物建模軟體市場，購買模式

  • 概要
  • 訂閱為基礎的
  • 一次性許可證

第11章 全球藥物建模軟體市場，各終端用戶

  • 概要
  • 製藥公司及生物科技企業
  • CRO
  • 研究機關
  • 法規當局
  • 其他

第12章 全球藥物建模軟體市場，各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第13章 全球藥物建模軟體市場:企業的形勢

第14章 SWOT分析

第15章 全球藥物建模軟體市場，企業簡介

  • DASSAULT SYSTEMES
  • AMAZON WEB SERVICES, INC. OR ITS AFFILIATES
  • CERTARA, USA
  • SCHRODINGER, INC
  • CRESSET
  • ACELLERA LTD
  • ARGUSLAB
  • ATOMWISE INC
  • BC PLATFORMS
  • BIOSOLVEIT GMBH
  • DOTMATICS
  • GENECODE
  • INSILICOTRIALS TECHNOLOGIES
  • NANOME INC
  • OPTIBRIUM, LTD.
  • PHARMACELERA
  • SIMULATIONS PLUS
  • THE SCRIPPS RESEARCH INSTITUTE
  • VERISIM LIFE

The drug modeling software market is expected to reach USD 16,808.81 million by 2030 from USD 8,504.35 million in 2022, growing at a CAGR of 9.2% during the forecast period of 2023 to 2033.

Market Segmentation:

Global Drug Modeling Software Market, By Component (Software, and Services), Operating System (Windows, Linux, Mac OS, and Others), Deployment Mode (Cloud Based, Hybrid Based, and On Premises), Enterprise Size(Large Enterprise Size, Small and Medium Enterprise Size), Application (Graphical Molecular Modeling, Gene Sequence Analysis, Protein Modeling, Modeling Crystal Structures, Cheminformatics, High Throughput Virtual Screening, Gas and Solution Phase Reaction, Medical Imaging, and Others), Purchase Model (Subscription Based, and One- Time License), End User( Pharmaceutical and Biotechnology Companies, Contract Research Organization, Research Institutes, Regulatory Authorities, and Others), Country ( U.S., Canada, Mexico, Germany, France , U.K., Italy, Russia, Spain, Turkey, Netherlands, Switzerland, Belgium,Poland,Sweden, Denmark, Finland, Norway, Rest of Europe, China, Japan , South Korea , India , Australia , Singapore, Thailand , Indonesia , Philippines , Malaysia , New Zealand , Vietnam , Taiwan, Rest Of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa , Saudi Arabia , UAE , Egypt, Israel , Oman , Bahrain , Kuwait , Qatar , Rest of Middle East and Africa - Industry Trends and Forecast to 2030.

Overview of Global Drug Modeling Software Market Dynamics :

  • Driver
  • Rising drug discovery and development activities
  • Restrain
  • Lack of quality data base
  • Opportunity
  • Cloud computing and big data analytics in drug modelling

Market Players:

The key market players operating in the drug modeling software market are listed below:

  • Dotmatics
  • BC Platforms
  • InSilicoTrials Technologies.
  • VeriSIM Life., Atomwise Inc.
  • Certara, USA.
  • GENECODE
  • Cresset., and Nanome Inc.
  • SIMULATIONS PLUS.
  • Dassault Systemes
  • Scripps Research
  • XtalPi Inc.
  • Xybion
  • ArgusLab
  • Schrodinger, Inc.

TABLE OF CONTENTS

1 INTRODUCTION 58

  • 1.1 OBJECTIVES OF THE STUDY 58
  • 1.2 MARKET DEFINITION 58
  • 1.3 OVERVIEW OF THE GLOBAL DRUG MODELING SOFTWARE MARKET 58
  • 1.4 CURRENCY AND PRICING 60
  • 1.5 LIMITATIONS 60
  • 1.6 MARKETS COVERED 60

2 MARKET SEGMENTATION 63

  • 2.1 MARKETS COVERED 63
  • 2.2 GEOGRAPHICAL SCOPE 64
  • 2.3 YEARS CONSIDERED FOR THE STUDY 65
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 66
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 69
  • 2.6 MULTIVARIATE MODELING 70
  • 2.7 COMPONENT LIFELINE CURVE 70
  • 2.8 DBMR MARKET POSITION GRID 71
  • 2.9 VENDOR SHARE ANALYSIS 72
  • 2.10 MARKET APPLICATION COVERAGE GRID 73
  • 2.11 SECONDARY SOURCES 74
  • 2.12 ASSUMPTIONS 74

3 EXECUTIVE SUMMARY 75

  • 3.1 PORTER'S FIVE FORCES MODEL 81
  • 3.2 VALUE CHAIN ANALYSIS 82
  • 3.3 REGULATORY STANDARDS 83
  • 3.4 TECHNOLOGICAL TRENDS 84
  • 3.5 BENEFITS OF DRUG MODELING SOFTWARE 85

4 MARKET OVERVIEW 86

  • 4.1 DRIVERS 88
    • 4.1.1 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 88
    • 4.1.2 RISING DEMAND FOR NOVEL THERAPIES 90
    • 4.1.3 PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING 91
  • 4.2 RESTRAINTS 92
    • 4.2.1 LACK OF QUALITY DATA BASE 92
    • 4.2.2 HIGH COST OF MANUFACTURING OF DRUG MODELLING SOFTWARE 92
  • 4.3 OPPORTUNITIES 93
    • 4.3.1 CLOUD COMPUTING AND BIG DATA ANALYTICS IN DRUG MODELLING 93
    • 4.3.2 INCREASING ADOPTION OF MODELLING TOOLS IN DRUG DISCOVERY 94
  • 4.4 CHALLENGES 94
    • 4.4.1 LACK OF PROCEDURE FOR MULTI-DRUG EFFECT ASSESMENT 94
    • 4.4.2 CHALLENGES WITH MODEL INTERPRETATION 95

5 GLOBAL DRUG MODELING SOFTWARE MARKET, BY COMPONENTS 96

  • 5.1 OVERVIEW 97
    • 5.1.1 SOFTWARE 100
      • 5.1.1.1 INTEGRATED 101
      • 5.1.1.2 STANDALONE 101
      • 5.1.1.3 LIGAND BASED 101
      • 5.1.1.4 STRUCTURE BASED 101
  • 5.2 SERVICES 101
    • 5.2.1 PROFESSIONAL SERVICES 102
      • 5.2.1.1 CONSULTING AND TRAINING 103
      • 5.2.1.2 INTEGRATION AND IMPLEMENTATION 103
      • 5.2.1.3 SUPPORT AND MAINTENANCE 103
    • 5.2.2 MANAGED SERVICES 103

6 GLOBAL DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM 104

  • 6.1 OVERVIEW 105
  • 6.2 WINDOWS 108
  • 6.3 LINUX 108
  • 6.4 MAC OS 109
  • 6.5 OTHERS 110

7 GLOBAL DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE 111

  • 7.1 OVERVIEW 112
  • 7.2 CLOUD BASED 115
  • 7.3 HYBRID-BASED 115
  • 7.4 ON-PREMISES 116

8 GLOBAL DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE 117

  • 8.1 OVERVIEW 118
  • 8.2 LARGE ENTERPRISE SIZE 121
  • 8.3 SMALL & MEDIUM ENTERPRISE SIZE 121

9 GLOBAL DRUG MODELING SOFTWARE MARKET, BY APPLICATION 123

  • 9.1 OVERVIEW 124
  • 9.2 GRAPHICAL MOLECULAR MODELING 127
  • 9.3 GENE SEQUENCE ANALYSIS 127
  • 9.4 PROTEIN MODELING 128
  • 9.5 MODELING CRYSTAL STRUCTURES 129
  • 9.6 CHEMINFORMATICS 130
  • 9.7 HIGH THROUGHPUT VIRTUAL SCREENING 131
  • 9.8 GAS & SOLUTION PHASE REACTION 131
  • 9.9 MEDICAL IMAGING 132
  • 9.10 OTHERS 133

10 GLOBAL DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL 134

  • 10.1 OVERVIEW 135
  • 10.2 SUBSCRIPTION BASED 138
    • 10.2.1 ANNUALLY SUBSCRIPTION 139
    • 10.2.2 MONTHLY SUBSCRIPTION 139
  • 10.3 ONE-TIME LICENSE 139
    • 10.3.1 GROUP LICENSE 140
    • 10.3.2 DESKTOP LICENSE 140
    • 10.3.3 OTHERS 140

11 GLOBAL DRUG MODELING SOFTWARE MARKET, BY END USER 141

  • 11.1 OVERVIEW 142
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 145
    • 11.2.1 LARGE ENTERPRISE SIZE 146
    • 11.2.2 SMALL & MEDIUM ENTERPRISE SIZE 146
  • 11.3 CONTRACT RESEARCH ORGANIZATIONS 146
    • 11.3.1 LARGE ENTERPRISE SIZE 147
    • 11.3.2 SMALL & MEDIUM ENTERPRISE SIZE 147
  • 11.4 RESEARCH INSTITUTES 147
    • 11.4.1 LARGE ENTERPRISE SIZE 148
    • 11.4.2 SMALL & MEDIUM ENTERPRISE SIZE 148
  • 11.5 REGULATORY AUTHORITIES 148
    • 11.5.1 LARGE ENTERPRISE SIZE 149
    • 11.5.2 SMALL & MEDIUM ENTERPRISE SIZE 150
  • 11.6 OTHERS 150
    • 11.6.1 LARGE ENTERPRISE SIZE 151
    • 11.6.2 SMALL & MEDIUM ENTERPRISE SIZE 151

12 GLOBAL DRUG MODELING SOFTWARE MARKET, BY REGION 152

  • 12.1 OVERVIEW 153
  • 12.2 NORTH AMERICA 159
    • 12.2.1 U.S. 169
    • 12.2.2 CANADA 174
    • 12.2.3 MEXICO 179
  • 12.3 EUROPE 184
    • 12.3.1 GERMANY 195
    • 12.3.2 FRANCE 200
    • 12.3.3 U.K. 205
    • 12.3.4 ITALY 210
    • 12.3.5 RUSSIA 215
    • 12.3.6 SPAIN 220
    • 12.3.7 TURKEY 225
    • 12.3.8 NETHERLANDS 230
    • 12.3.9 SWITZERLAND 235
    • 12.3.10 BELGIUM 240
    • 12.3.11 POLAND 245
    • 12.3.12 SWEDEN 250
    • 12.3.13 DENMARK 255
    • 12.3.14 FINLAND 260
    • 12.3.15 NORWAY 265
    • 12.3.16 REST OF EUROPE 270
  • 12.4 ASIA-PACIFIC 271
    • 12.4.1 CHINA 282
    • 12.4.2 JAPAN 287
    • 12.4.3 SOUTH KOREA 292
    • 12.4.4 INDIA 297
    • 12.4.5 AUSTRALIA 302
    • 12.4.6 SINGAPORE 307
    • 12.4.7 THAILAND 312
    • 12.4.8 INDONESIA 317
    • 12.4.9 PHILIPPINES 322
    • 12.4.10 MALAYSIA 327
    • 12.4.11 NEW ZEALAND 332
    • 12.4.12 VIETNAM 337
    • 12.4.13 TAIWAN 342
    • 12.4.14 REST OF ASIA-PACIFIC 347
  • 12.5 SOUTH AMERICA 348
    • 12.5.1 BRAZIL 359
    • 12.5.2 ARGENTINA 364
    • 12.5.3 REST OF SOUTH AMERICA 369
  • 12.6 MIDDLE EAST AND AFRICA 370
    • 12.6.1 SOUTH AFRICA 380
    • 12.6.2 SAUDI ARABIA 385
    • 12.6.3 U.A.E. 390
    • 12.6.4 EGYPT 395
    • 12.6.5 ISRAEL 400
    • 12.6.6 OMAN 405
    • 12.6.7 BAHRAIN 410
    • 12.6.8 KUWAIT 415
    • 12.6.9 QATAR 420
    • 12.6.10 REST OF MIDDLE EAST AND AFRICA 425

13 GLOBAL DRUG MODELING SOFTWARE MARKET: COMPANY LANDSCAPE 426

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL 426
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 427
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE 428
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 429

14 SWOT ANALYSIS 430

15 GLOBAL DRUG MODELING SOFTWARE MARKET, COMPANY PROFILE 431

  • 15.1 DASSAULT SYSTEMES 431
    • 15.1.1 COMPANY SNAPSHOT 431
    • 15.1.2 REVENUE ANALYSIS 431
    • 15.1.3 COMPANY SHARE ANALYSIS 432
    • 15.1.4 PRODUCT PORTFOLIO 432
    • 15.1.5 RECENT DEVELOPMENT 432
  • 15.2 AMAZON WEB SERVICES, INC. OR ITS AFFILIATES.(A SUBSIDIARY OF AMAZON) 433
    • 15.2.1 COMPANY SNAPSHOT 433
    • 15.2.2 REVENUE ANALYSIS 433
    • 15.2.3 COMPANY SHARE ANALYSIS 434
    • 15.2.4 PRODUCT PORTFOLIO 434
    • 15.2.5 RECENT DEVELOPMENTS 434
  • 15.3 CERTARA, USA. 435
    • 15.3.1 COMPANY SNAPSHOT 435
    • 15.3.2 REVENUE ANALYSIS 435
    • 15.3.3 COMPANY SHARE ANALYSIS 436
    • 15.3.4 PRODUCT PORTFOLIO 436
    • 15.3.5 RECENT DEVELOPMENTS 436
  • 15.4 SCHRODINGER, INC. 437
    • 15.4.1 COMPANY SNAPSHOT 437
    • 15.4.2 REVENUE ANALYSIS 437
    • 15.4.3 COMPANY SHARE ANALYSIS 438
    • 15.4.4 PRODUCT PORTFOLIO 438
    • 15.4.5 RECENT DEVELOPMENT 438
  • 15.5 CRESSET. 439
    • 15.5.1 COMPANY SNAPSHOT 439
    • 15.5.2 COMPANY SHARE ANALYSIS 439
    • 15.5.3 PRODUCT PORTFOLIO 440
    • 15.5.4 RECENT DEVELOPMENTS 440
  • 15.6 ACELLERA LTD 441
    • 15.6.1 COMPANY SNAPSHOT 441
    • 15.6.2 PRODUCT PORTFOLIO 441
    • 15.6.3 RECENT DEVELOPMENTS 441
  • 15.7 ARGUSLAB 442
    • 15.7.1 COMPANY SNAPSHOT 442
    • 15.7.2 PRODUCT PORTFOLIO 442
    • 15.7.3 RECENT DEVELOPMENT 442
  • 15.8 ATOMWISE INC. 443
    • 15.8.1 COMPANY SNAPSHOT 443
    • 15.8.2 PRODUCT PORTFOLIO 443
    • 15.8.3 RECENT DEVELOPMENT 443
  • 15.9 BC PLATFORMS 444
    • 15.9.1 COMPANY SNAPSHOT 444
    • 15.9.2 PRODUCT PORTFOLIO 444
    • 15.9.3 RECENT DEVELOPMENTS 445
  • 15.10 BIOSOLVEIT GMBH 446
    • 15.10.1 COMPANY SNAPSHOT 446
    • 15.10.2 PRODUCT PORTFOLIO 446
    • 15.10.3 RECENT DEVELOPMENT 446
  • 15.11 DOTMATICS 447
    • 15.11.1 COMPANY SNAPSHOT 447
    • 15.11.2 PRODUCT PORTFOLIO 447
    • 15.11.3 RECENT DEVELOPMENTS 448
  • 15.12 GENECODE 449
    • 15.12.1 COMPANY SNAPSHOT 449
    • 15.12.2 PRODUCT PORTFOLIO 449
    • 15.12.3 RECENT DEVELOPMENT 449
  • 15.13 INSILICOTRIALS TECHNOLOGIES. 450
    • 15.13.1 COMPANY SNAPSHOT 450
    • 15.13.2 PRODUCT PORTFOLIO 450
    • 15.13.3 RECENT DEVELOPMENTS 451
  • 15.14 NANOME INC. 452
    • 15.14.1 COMPANY SNAPSHOT 452
    • 15.14.2 PRODUCT PORTFOLIO 452
    • 15.14.3 RECENT DEVELOPMENT 452
  • 15.15 OPTIBRIUM, LTD. 453
    • 15.15.1 COMPANY SNAPSHOT 453
    • 15.15.2 PRODUCT PORTFOLIO 453
    • 15.15.3 RECENT DEVELOPMENT 453
  • 15.16 PHARMACELERA 454
    • 15.16.1 COMPANY SNAPSHOT 454
    • 15.16.2 PRODUCT PORTFOLIO 454
    • 15.16.3 RECENT DEVELOPMENT 454
  • 15.17 SIMULATIONS PLUS. 455
    • 15.17.1 COMPANY SNAPSHOT 455
    • 15.17.2 REVENUE ANALYSIS 456
    • 15.17.3 COMPANY SHARE ANALYSIS 457
    • 15.17.4 PRODUCT PORTFOLIO 457
    • 15.17.5 RECENT DEVELOPMENT 458
  • 15.18 THE SCRIPPS RESEARCH INSTITUTE 459
    • 15.18.1 COMPANY SNAPSHOT 459
    • 15.18.2 PRODUCT PORTFOLIO 459
    • 15.18.3 RECENT DEVELOPMENT 459
  • 15.19 VERISIM LIFE. 460
    • 15.19.1 COMPANY SNAPSHOT 460
    • 15.19.2 PRODUCT PORTFOLIO 460
    • 15.19.3 RECENT DEVELOPMENTS 460
  • 15.20 XTALPI INC. 461
    • 15.20.1 COMPANY SNAPSHOT 461
    • 15.20.2 PRODUCT PORTFOLIO 461
    • 15.20.3 RECENT DEVELOPMENT 461
  • 15.21 XYBION DIGITAL INC. 462
    • 15.21.1 COMPANY SNAPSHOT 462
    • 15.21.2 REVENUE ANALYSIS 462
    • 15.21.3 PRODUCT PORTFOLIO 463
    • 15.21.4 RECENT DEVELOPMENT 463

16 QUESTIONNAIRE 464

17 RELATED REPORTS 468

LIST OF TABLES

  • TABLE 1 GLOBAL DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 99
  • TABLE 2 GLOBAL SOFTAWARE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 100
  • TABLE 3 GLOBAL SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 100
  • TABLE 4 GLOBAL SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 101
  • TABLE 5 GLOBAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 102
  • TABLE 6 GLOBAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 7 GLOBAL PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 8 GLOBAL DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 107
  • TABLE 9 GLOBAL WINDOWS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 108
  • TABLE 10 GLOBAL LINUX IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 109
  • TABLE 11 GLOBAL MAC OS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 109
  • TABLE 12 GLOBAL OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 110
  • TABLE 13 GLOBAL DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 114
  • TABLE 14 GLOBAL CLOUD BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 115
  • TABLE 15 GLOBAL HYBRID-BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 116
  • TABLE 16 GLOBAL ON-PREMISES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 116
  • TABLE 17 GLOBAL DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 120
  • TABLE 18 GLOBAL LARGE ENTERPRISE SIZE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 121
  • TABLE 19 GLOBAL SMALL & MEDIUM ENTERPRISE SIZE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 122
  • TABLE 20 GLOBAL DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 126
  • TABLE 21 GLOBAL GRAPHICAL MOLECULAR MODELING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 22 GLOBAL GENE SEQUENCE ANALYSIS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 128
  • TABLE 23 GLOBAL PROTEIN MODELING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 129
  • TABLE 24 GLOBAL MODELING CRYSTAL STRUCTURES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 130
  • TABLE 25 GLOBAL CHEMINFORMATICS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 130
  • TABLE 26 GLOBAL HIGH THROUGHPUT VIRTUAL SCREENING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 131
  • TABLE 27 GLOBAL GAS & SOLUTION PHASE REACTION IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 132
  • TABLE 28 GLOBAL MEDICAL IMAGING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 133
  • TABLE 29 GLOBAL OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 133
  • TABLE 30 GLOBAL DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 137
  • TABLE 31 GLOBAL SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 138
  • TABLE 32 GLOBAL SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 138
  • TABLE 33 GLOBAL ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 139
  • TABLE 34 GLOBAL ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 140
  • TABLE 35 GLOBAL DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 144
  • TABLE 36 GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 145
  • TABLE 37 GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 145
  • TABLE 38 GLOBAL CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 146
  • TABLE 39 GLOBAL CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 147
  • TABLE 40 GLOBAL RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 148
  • TABLE 41 GLOBAL RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 148
  • TABLE 42 GLOBAL REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 149
  • TABLE 43 GLOBAL REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 149
  • TABLE 44 GLOBAL OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 150
  • TABLE 45 GLOBAL OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 150
  • TABLE 46 GLOBAL DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 158
  • TABLE 47 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 164
  • TABLE 48 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 164
  • TABLE 49 NORTH AMERICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 50 NORTH AMERICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 51 NORTH AMERICA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 52 NORTH AMERICA PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 53 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 165
  • TABLE 54 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 165
  • TABLE 55 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 166
  • TABLE 56 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
  • TABLE 57 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 166
  • TABLE 58 NORTH AMERICA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 167
  • TABLE 59 NORTH AMERICA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 167
  • TABLE 60 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 167
  • TABLE 61 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 167
  • TABLE 62 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 168
  • TABLE 63 NORTH AMERICA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 168
  • TABLE 64 NORTH AMERICA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 168
  • TABLE 65 NORTH AMERICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 168
  • TABLE 66 U.S. DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 169
  • TABLE 67 U.S. SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 68 U.S. SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 69 U.S. SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 70 U.S. PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 71 U.S. DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 170
  • TABLE 72 U.S. DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 170
  • TABLE 73 U.S. DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 170
  • TABLE 74 U.S. DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 171
  • TABLE 75 U.S. DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 171
  • TABLE 76 U.S. SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 171
  • TABLE 77 U.S. ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 172
  • TABLE 78 U.S. DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 172
  • TABLE 79 U.S. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 172
  • TABLE 80 U.S. CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 172
  • TABLE 81 U.S. RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 173
  • TABLE 82 U.S. REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 173
  • TABLE 83 U.S. OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 173
  • TABLE 84 CANADA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 174
  • TABLE 85 CANADA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 86 CANADA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 87 CANADA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 88 CANADA PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 89 CANADA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 175
  • TABLE 90 CANADA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 175
  • TABLE 91 CANADA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 175
  • TABLE 92 CANADA DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 176
  • TABLE 93 CANADA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 176
  • TABLE 94 CANADA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 176
  • TABLE 95 CANADA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 177
  • TABLE 96 CANADA DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 177
  • TABLE 97 CANADA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 177
  • TABLE 98 CANADA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 177
  • TABLE 99 CANADA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 178
  • TABLE 100 CANADA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 178
  • TABLE 101 CANADA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 178
  • TABLE 102 MEXICO DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 179
  • TABLE 103 MEXICO SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 104 MEXICO SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 105 MEXICO SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 106 MEXICO PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 180
  • TABLE 107 MEXICO DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 180
  • TABLE 108 MEXICO DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 180
  • TABLE 109 MEXICO DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 180
  • TABLE 110 MEXICO DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 181
  • TABLE 111 MEXICO DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 181
  • TABLE 112 MEXICO SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 181
  • TABLE 113 MEXICO ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 182
  • TABLE 114 MEXICO DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 182
  • TABLE 115 MEXICO PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 182
  • TABLE 116 MEXICO CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 182
  • TABLE 117 MEXICO RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 183
  • TABLE 118 MEXICO REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 183
  • TABLE 119 MEXICO OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 183
  • TABLE 120 EUROPE DRUG MODELING SOFTWARE MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 189
  • TABLE 121 EUROPE DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 189
  • TABLE 122 EUROPE SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 189
  • TABLE 123 EUROPE SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 190
  • TABLE 124 EUROPE SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 190
  • TABLE 125 EUROPE PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 190
  • TABLE 126 EUROPE DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 190
  • TABLE 127 EUROPE DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 191
  • TABLE 128 EUROPE DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 191
  • TABLE 129 EUROPE DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 191
  • TABLE 130 EUROPE DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 192
  • TABLE 131 EUROPE SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 192
  • TABLE 132 EUROPE ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 192
  • TABLE 133 EUROPE DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 192
  • TABLE 134 EUROPE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 193
  • TABLE 135 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 193
  • TABLE 136 EUROPE RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 193
  • TABLE 137 EUROPE REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 193
  • TABLE 138 EUROPE OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 194
  • TABLE 139 GERMANY DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 195
  • TABLE 140 GERMANY SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 195
  • TABLE 141 GERMANY SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 195
  • TABLE 142 GERMANY SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 195
  • TABLE 143 GERMANY PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 196
  • TABLE 144 GERMANY DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 196
  • TABLE 145 GERMANY DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 196
  • TABLE 146 GERMANY DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 196
  • TABLE 147 GERMANY DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 197
  • TABLE 148 GERMANY DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 197
  • TABLE 149 GERMANY SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 197
  • TABLE 150 GERMANY ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 198
  • TABLE 151 GERMANY DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 198
  • TABLE 152 GERMANY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 198
  • TABLE 153 GERMANY CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 198
  • TABLE 154 GERMANY RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 199
  • TABLE 155 GERMANY REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 199
  • TABLE 156 GERMANY OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 199
  • TABLE 157 FRANCE DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 200
  • TABLE 158 FRANCE SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 200
  • TABLE 159 FRANCE SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 200
  • TABLE 160 FRANCE SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 200
  • TABLE 161 FRANCE PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 201
  • TABLE 162 FRANCE DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 201
  • TABLE 163 FRANCE DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 201
  • TABLE 164 FRANCE DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 201
  • TABLE 165 FRANCE DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 202
  • TABLE 166 FRANCE DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 202
  • TABLE 167 FRANCE SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 202
  • TABLE 168 FRANCE ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 203
  • TABLE 169 FRANCE DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 203
  • TABLE 170 FRANCE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 203
  • TABLE 171 FRANCE CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 203
  • TABLE 172 FRANCE RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 204
  • TABLE 173 FRANCE REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 204
  • TABLE 174 FRANCE OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 204
  • TABLE 175 U.K. DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 205
  • TABLE 176 U.K. SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 205
  • TABLE 177 U.K. SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 205
  • TABLE 178 U.K. SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 205
  • TABLE 179 U.K. PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 206
  • TABLE 180 U.K. DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 206
  • TABLE 181 U.K. DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 206
  • TABLE 182 U.K. DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 206
  • TABLE 183 U.K. DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 207
  • TABLE 184 U.K. DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 207
  • TABLE 185 U.K. SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 207

LIST OF FIGURES

  • FIGURE 1 GLOBAL DRUG MODELING SOFTWARE MARKET: SEGMENTATION 63
  • FIGURE 2 GLOBAL DRUG MODELING SOFTWARE MARKET: DATA TRIANGULATION 66
  • FIGURE 3 GLOBAL DRUG MODELING SOFTWARE MARKET: DROC ANALYSIS 67
  • FIGURE 4 GLOBAL DRUG MODELING SOFTWARE MARKET: GLOBAL VS. REGIONAL MARKET ANALYSIS 68
  • FIGURE 5 GLOBAL DRUG MODELING SOFTWARE MARKET: COMPANY RESEARCH ANALYSIS 68
  • FIGURE 6 GLOBAL DRUG MODELING SOFTWARE MARKET: INTERVIEW DEMOGRAPHICS 69
  • FIGURE 7 GLOBAL DRUG MODELING SOFTWARE MARKET: MULTIVARIATE MODELING 70
  • FIGURE 8 GLOBAL DRUG MODELING SOFTWARE MARKET: DBMR MARKET POSITION GRID 71
  • FIGURE 9 GLOBAL DRUG MODELING SOFTWARE MARKET: VENDOR SHARE ANALYSIS 72
  • FIGURE 10 GLOBAL DRUG MODELING SOFTWARE MARKET: MARKET APPLICATION COVERAGE GRID 73
  • FIGURE 11 GLOBAL DRUG MODELING SOFTWARE MARKET: SEGMENTATION 77
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL DRUG MODELING SOFTWAREMARKET, AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2023 TO 2030 78
  • FIGURE 13 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES, RISING DEMAND FOR NOVEL THERAPIES, AND PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING ARE ARE EXPECTED TO DRIVE THE GLOBAL DRUG MODELING SOFTWARE MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030 79
  • FIGURE 14 SOFTWARE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DRUG MODELING SOFTWARE MARKET IN 2023 & 2030 79
  • FIGURE 15 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR THE DRUG MODELING SOFTWARE MANUFACTURERS IN THE FORECAST PERIOD FROM 2023 TO 2030 80
  • FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DRUG MODELING SOFTWARE MARKET 87
  • FIGURE 17 GLOBAL DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, 2022 97
  • FIGURE 18 GLOBAL DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, 2023-2030 (USD MILLION) 98
  • FIGURE 19 GLOBAL DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, CAGR (2023-2030) 98
  • FIGURE 20 GLOBAL DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, LIFELINE CURVE 99
  • FIGURE 21 GLOBAL DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, 2022 105
  • FIGURE 22 GLOBAL DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, 2023-2030 (USD MILLION) 106
  • FIGURE 23 GLOBAL DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, CAGR (2023-2030) 106
  • FIGURE 24 GLOBAL DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, LIFELINE CURVE 107
  • FIGURE 25 GLOBAL DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, 2022 112
  • FIGURE 26 GLOBAL DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, 2023-2030 (USD MILLION) 113
  • FIGURE 27 GLOBAL DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, CAGR (2023-2030) 113
  • FIGURE 28 GLOBAL DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, LIFELINE CURVE 114
  • FIGURE 29 GLOBAL DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, 2022 118
  • FIGURE 30 GLOBAL DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, 2023-2030 (USD MILLION) 119
  • FIGURE 31 GLOBAL DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, CAGR (2023-2030) 119
  • FIGURE 32 GLOBAL DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, LIFELINE CURVE 120
  • FIGURE 33 GLOBAL DRUG MODELING SOFTWARE MARKET: BY APPLICATION, 2022 124
  • FIGURE 34 GLOBAL DRUG MODELING SOFTWARE MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 125
  • FIGURE 35 GLOBAL DRUG MODELING SOFTWARE MARKET: BY APPLICATION, CAGR (2023-2030) 125
  • FIGURE 36 GLOBAL DRUG MODELING SOFTWARE MARKET: BY APPLICATION, LIFELINE CURVE 126
  • FIGURE 37 GLOBAL DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, 2022 135
  • FIGURE 38 GLOBAL DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, 2023-2030 (USD MILLION) 136
  • FIGURE 39 GLOBAL DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, CAGR (2023-2030) 136
  • FIGURE 40 GLOBAL DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, LIFELINE CURVE 137
  • FIGURE 41 GLOBAL DRUG MODELING SOFTWARE MARKET: BY END USER, 2022 142
  • FIGURE 42 GLOBAL DRUG MODELING SOFTWARE MARKET: BY END USER, 2023-2030 (USD MILLION) 143
  • FIGURE 43 GLOBAL DRUG MODELING SOFTWARE MARKET: BY END USER, CAGR (2023-2030) 143
  • FIGURE 44 GLOBAL DRUG MODELING SOFTWARE MARKET: BY END USER, LIFELINE CURVE 144
  • FIGURE 45 GLOBAL DRUG MODELING SOFTWARE MARKET: SNAPSHOT (2022) 154
  • FIGURE 46 GLOBAL DRUG MODELING SOFTWARE MARKET: BY REGION (2022) 156
  • FIGURE 47 GLOBAL DRUG MODELING SOFTWARE MARKET: BY REGION (2023 & 2030) 156
  • FIGURE 48 GLOBAL DRUG MODELING SOFTWARE MARKET: BY REGION (2022 & 2030) 157
  • FIGURE 49 GLOBAL DRUG MODELING SOFTWARE MARKET: BY COMPONENTS (2023-2030) 157
  • FIGURE 50 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: SNAPSHOT (2022) 160
  • FIGURE 51 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022) 162
  • FIGURE 52 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2023 & 2030) 162
  • FIGURE 53 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022 & 2030) 163
  • FIGURE 54 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS (2023-2030) 163
  • FIGURE 55 EUROPE DRUG MODELING SOFTWARE MARKET: SNAPSHOT (2022) 185
  • FIGURE 56 EUROPE DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022) 187
  • FIGURE 57 EUROPE DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2023 & 2030) 187
  • FIGURE 58 EUROPE DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022 & 2030) 188
  • FIGURE 59 EUROPE DRUG MODELING SOFTWARE MARKET: BY COMPONENTS (2023-2030) 188
  • FIGURE 60 ASIA-PACIFIC DRUG MODELING SOFTWARE MARKET: SNAPSHOT (2022) 272
  • FIGURE 61 ASIA-PACIFIC DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022) 274
  • FIGURE 62 ASIA-PACIFIC DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2023 & 2030) 274
  • FIGURE 63 ASIA-PACIFIC DRUG MODELING SOFTWARE MARKET: BY COMPONENTS (2023-2030) 275
  • FIGURE 64 SOUTH AMERICA DRUG MODELING SOFTWARE MARKET: SNAPSHOT (2022) 349
  • FIGURE 65 SOUTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022) 351
  • FIGURE 66 SOUTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2023 & 2030) 351
  • FIGURE 67 SOUTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022 & 2030) 352
  • FIGURE 68 SOUTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS (2023-2030) 352
  • FIGURE 69 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET: SNAPSHOT (2022) 371
  • FIGURE 70 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022) 373
  • FIGURE 71 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2023 & 2030) 373
  • FIGURE 72 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022 & 2030) 374
  • FIGURE 73 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS (2023-2030) 374
  • FIGURE 74 GLOBAL DRUG MODELING SOFTWARE MARKET: COMPANY SHARE 2022 (%) 426
  • FIGURE 75 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: COMPANY SHARE 2022 (%) 427
  • FIGURE 76 EUROPE DRUG MODELING SOFTWARE MARKET: COMPANY SHARE 2022 (%) 428
  • FIGURE 77 ASIA-PACIFIC DRUG MODELING SOFTWARE MARKET: COMPANY SHARE 2022 (%) 429